Chardan Capital Reaffirms Buy Rating for SAB Biotherapeutics (NASDAQ:SABS)

Chardan Capital restated their buy rating on shares of SAB Biotherapeutics (NASDAQ:SABS) in a research note released on Wednesday,Benzinga reports. Chardan Capital currently has a $25.00 price objective on the stock.

Several other equities research analysts have also recently issued reports on SABS. Craig Hallum began coverage on SAB Biotherapeutics in a research note on Wednesday, October 9th. They issued a “buy” rating and a $11.00 price target for the company. HC Wainwright reaffirmed a “buy” rating and issued a $6.00 price objective on shares of SAB Biotherapeutics in a report on Wednesday. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, SAB Biotherapeutics presently has a consensus rating of “Buy” and an average price target of $12.40.

SAB Biotherapeutics Stock Performance

SABS stock opened at $2.23 on Wednesday. SAB Biotherapeutics has a fifty-two week low of $2.01 and a fifty-two week high of $6.30. The company has a current ratio of 3.69, a quick ratio of 3.69 and a debt-to-equity ratio of 0.09. The business’s fifty day moving average price is $3.63 and its two-hundred day moving average price is $3.13.

SAB Biotherapeutics (NASDAQ:SABS) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($1.12) EPS for the quarter, missing the consensus estimate of ($1.07) by ($0.05). SAB Biotherapeutics had a negative net margin of 1,450.14% and a negative return on equity of 94.37%. As a group, analysts anticipate that SAB Biotherapeutics will post -3.69 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in SAB Biotherapeutics stock. Kovitz Investment Group Partners LLC bought a new stake in SAB Biotherapeutics, Inc. (NASDAQ:SABS) during the third quarter, according to the company in its most recent disclosure with the SEC. The firm bought 19,201 shares of the company’s stock, valued at approximately $52,000. Kovitz Investment Group Partners LLC owned approximately 0.21% of SAB Biotherapeutics as of its most recent filing with the SEC. 7.82% of the stock is owned by institutional investors.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.